cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Roivant Sciences Ltd
13 own
5 watching
Current Price
$11.11
$-0.14
(-1.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6,962.79M
52-Week High
52-Week High
13.24000
52-Week Low
52-Week Low
8.24500
Average Volume
Average Volume
5.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization6,962.79M
icon52-Week High13.24000
icon52-Week Low8.24500
iconAverage Volume5.71M
iconDividend Yield--
iconP/E Ratio--
What does the Roivant Sciences Ltd do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Read More
How much money does Roivant Sciences Ltd make?
News & Events about Roivant Sciences Ltd.
Globe Newswire
1 year ago
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all dosesA Phase 2 study of RVT-3101 in Crohns disease has been initiated with topline data ...
Globe Newswire
1 year ago
46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (PAll secondary ...
Globe Newswire
1 year ago
PVTX-321 and PVTX-405 Achieve Development Candidate NominationNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics,aRoivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients ...
Zolmax
1 year ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) Director Vivek Ramaswamy sold 4,000,000 shares of the businesss stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $7.95, for a total value of $31,800,000.00. Following the completion of the transaction, ...
Globe Newswire
1 year ago
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the companys board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant in 2014 ...
Frequently Asked Questions
Frequently Asked Questions
What is Roivant Sciences Ltd share price today?
plus_minus_icon
Can Indians buy Roivant Sciences Ltd shares?
plus_minus_icon
How can I buy Roivant Sciences Ltd shares from India?
plus_minus_icon
Can Fractional shares of Roivant Sciences Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Roivant Sciences Ltd stocks?
plus_minus_icon
What is today’s traded volume of Roivant Sciences Ltd?
plus_minus_icon
What is today’s market capitalisation of Roivant Sciences Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Roivant Sciences Ltd?
plus_minus_icon
What percentage is Roivant Sciences Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Roivant Sciences Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$11.11
$-0.14
(-1.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00